MTN-033 was a Phase I study that looked at the safety and distribution of dapivirine gel when administered rectally as a lubricant (without an applicator) and whether enough drug is delivered in the tissue to feasibly provide HIV protection. The study was conducted in the U.S. and enrolled 16 HIV-negative cisgender men who have sex with men. Results, which were reported in February 2021 during the virtual HIV R4P conference, found higher than expected levels of drug in rectal tissue, but that dapivirine did not remain in tissue long enough to be able to provide sustained protection. (See also MTN-026).
Bottoms Are Up at the HIV Research for Prevention Virtual Conference